Figure 2

Combined anti-TIM-3/CD137 mAb treatment induced tumor-specific long-lasting protection against ID8 ovarian cancer requiring CD4⁺and CD8⁺T cells. The long-term survivors (90 days after first tumor challenge) pooled from 2 experiments were rechallenged (3 mice/group) with ID8 cells given i.p. or s.c. or with TC1 cells transplanted s.c. (A); naive mice were transplanted with tumor cells as controls (B). The survival of mice was recorded. C and D, Mice (5/group) treated with combined anti-TIM-3/CD137 mAb were also injected with an anti-CD4, anti-CD8, anti-CD4/CD8, anti-NK1.1, anti-CD19, or control mAb with 250 μg of each mAb per mouse 1 day before and two days after tumor challenge and every 5 days thereafter for the duration of the experiments. Tumor-bearing untreated mice were as negative controls (UNT). Data are representative of 2 experiments. *P < 0.05, s.c.TC1 compared with s.c.ID8 or i.p.ID8 in A; control depletion compared with CD4, CD8 or CD4/8 depletion in C; UNT compared with control, NK1.1 or CD19 depletion in D.